Trastuzumab Deruxtecan Continues to Reshape HER2+ Breast Cancer Treatment Paradigm
October 17th 2023
Lubna Chaudhary, MD, MS, discusses how findings from the various DESTINY-Breast trials affected the treatment landscape in HER2-positive breast cancer, the trials’ impact on the treatment arena, the evolving treatment landscape for patients with HER2-positive breast cancer, and the importance of staying updated on new drugs and clinical trials.